Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG012 · 1 trial · 1 indication
Incidence and severity of adverse events
Change in miR-21 expression in renal tissue
| Arm | Type | Description |
|---|---|---|
| RG-012 Single Dose | EXPERIMENTAL | 1.5 mg/kg RG012 subcutaneous injection |
| RG012 Every Other Week | EXPERIMENTAL | 1.5 mg/kg RG012 subcutaneous injections every other week |
| Name | Type | Description |
|---|---|---|
| RG012 | DRUG | RG012 in 0.3% sodium chloride |
Inclusion Criteria: 1. Males or females, ages 18 to 65 years 2. Confirmed diagnosis of Alport syndrome 3. eGFR between 40 and 90 mL/min/1.73m2 4. Proteinuria of at least 300 mg protein/g creatinine 5. For subjects taking an ACE inhibitor or an ARB, the dosing regimen should be stable for at least 3...
RG012 is an investigational small molecule being developed for the treatment of Alport Syndrome, a genetic condition affecting the kidneys. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
RG012 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 1 clinical trials for Alport Syndrome.
RG012 is in Phase 1 clinical development. A Phase 1 study of RG012 in subjects with Alport Syndrome has been completed, but the drug remains investigational and has not received regulatory approval.
RG012 has one completed clinical trial, NCT03373786, titled "A Study of RG-012 in Subjects With Alport Syndrome." This Phase 1 study enrolled 4 participants in the United States and was a double-blind, controlled trial.
Yes, RG012 is also referred to as RG-012 in clinical trial documentation. The completed Phase 1 study, NCT03373786, uses the name RG-012 in its title, confirming that both names refer to the same investigational drug.